Principal Investigator: ADCS Clinical Trial [ Bio ]
Site Leader: Paul Rosenberg, M.D.
The goal of this study is to determine whether treatment with Valproate delays the emergence of agitation and/or psychosis in patients with Alzheimer’s disease (AD). Mild-to-moderately impaired patients with AD who have not experienced agitation and psychosis are eligible. Some of the patients will get the actual medication and some will get a placebo (sugar pill). Participants will have regular clinic visits as well as telephone contacts for assessment of behavior, cognition, function, safety and tolerability. Biological specimens will be taken at regular intervals. MRI scans will be performed prior to experimental treatment and after one year in a subset of participant. The primary hypothesis is that chronic valproate administration to participants with AD who lack agitation and psychosis at baseline will delay the emergence of agitation and/or psychosis. Enrollment in this study is complete.
For more information regarding this study, please call 410-955-8702.
|
